Raghunath Anant Mashelkar

Raghunath Anant Mashelkar

Auto-generated profile, based on publicly available information

Raghunath Anant Mashelkar

National Chemical Laboratory, Pune 411008, India;

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
APAmeya Phadke
Ameya Phadke
CZChao Zhang
Chao Zhang
BABedri Arman
Bedri Arman
CHCheng-Chih Hsu
Cheng-Chih Hsu
RMRaghunath A. Mashelkar
Raghunath A. Mashelkar
SVShyni Varghese
Shyni Varghese
Synthetic materials that are capable of autonomous healing upon damage are being developed at a rapid pace because of their many potential applications. Despite these advancements, achieving self-healing in permanently cross-linked hydrogels has remained elusive because of the presence of water and irreversible cross-links. Here, we demonstrate that permanently cross-linked hydrogels can be engineered to exhibit self-healing in an aqueous environment. We achieve this feature by arming the hydrogel network with flexible-pendant side chains carrying an optimal balance of hydrophilic and hydrophobic moieties that allows the side chains to mediate hydrogen bonds across the hydrogel interfaces with minimal steric hindrance and hydrophobic collapse. The self-healing reported here is rapid, occurring within seconds of the insertion of a crack into the hydrogel or juxtaposition of two separate hydrogel pieces. The healing is reversible and can be switched on and off via changes in pH, allowing external control over the healing process. Moreover, the hydrogels can sustain multiple cycles of healing and separation without compromising their mechanical properties and healing kinetics. Beyond revealing how secondary interactions could be harnessed to introduce new functions to chemically cross-linked polymeric systems, we also demonstrate various potential applications of such easy-to-synthesize, smart, self-healing hydrogels.

23 June 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
APAbhimanyu S. Paraskar
Abhimanyu S. Paraskar
SSShivani Soni
Shivani Soni
KCKenneth T. Chin
Kenneth T. Chin
PCPadmaparna Chaudhuri
Padmaparna Chaudhuri
KMKatherine W. Muto
Katherine W. Muto
SSShiladitya Sengupta
Shiladitya Sengupta
Cisplatin is a first line chemotherapy for most types of cancer. However, its use is dose-limited due to severe nephrotoxicity. Here we report the rational engineering of a novel nanoplatinate inspired by the mechanisms underlying cisplatin bioactivation. We engineered a novel polymer, glucosamine-functionalized polyisobutylene-maleic acid, where platinum (Pt) can be complexed to the monomeric units using a monocarboxylato and an O → Pt coordinate bond. We show that at a unique platinum to polymer ratio, this complex self-assembles into a nanoparticle, which releases cisplatin in a pH-dependent manner. The nanoparticles are rapidly internalized into the endolysosomal compartment of cancer cells, and exhibit an IC50 (4.25 ± 0.16 μM) comparable to that of free cisplatin (3.87 ± 0.37 μM), and superior to carboplatin (14.75 ± 0.38 μM). The nanoparticles exhibited significantly improved antitumor efficacy in terms of tumor growth delay in breast and lung cancers and tumor regression in a K-rasLSL/+/Ptenfl/flovarian cancer model. Furthermore, the nanoparticle treatment resulted in reduced systemic and nephrotoxicity, validated by decreased biodistribution of platinum to the kidney as quantified using inductively coupled plasma spectroscopy. Given the universal need for a better platinate, we anticipate this coupling of nanotechnology and structure-activity relationship to rationally reengineer cisplatin could have a major impact globally in the clinical treatment of cancer.

12 May 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SBSudipta Basu
Sudipta Basu
RHRania Harfouche
Rania Harfouche
SSShivani Soni
Shivani Soni
GCGeetanjali Chimote
Geetanjali Chimote
RMRaghunath A. Mashelkar
Raghunath A. Mashelkar
SSShiladitya Sengupta
Shiladitya Sengupta
The MAPK signal transduction cascade is dysregulated in a majority of human tumors. Here we report that a nanoparticle-mediated targeting of this pathway can optimize cancer chemotherapy. We engineered nanoparticles from a unique hexadentate-polyD,L-lactic acid-co-glycolic acid polymer chemically conjugated to PD98059, a selective MAPK inhibitor. The nanoparticles are taken up by cancer cells through endocytosis and demonstrate sustained release of the active agent, resulting in the inhibition of phosphorylation of downstream extracellular signal regulated kinase. We demonstrate that nanoparticle-mediated targeting of MAPK inhibits the proliferation of melanoma and lung carcinoma cells and induces apoptosis in vitro. Administration of the PD98059-nanoparticles in melanoma-bearing mice inhibits tumor growth and enhances the antitumor efficacy of cisplatin chemotherapy. Our study shows the nanoparticle-mediated delivery of signal transduction inhibitors can emerge as a unique paradigm in cancer chemotherapy.

29 March 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AKAshish Kulkarni
Ashish Kulkarni
PRPoornima Rao
Poornima Rao
SNSiva Natarajan
Siva Natarajan
AGAaron Goldman
Aaron Goldman
VSVenkata S. Sabbisetti
Venkata S. Sabbisetti
SSShiladitya Sengupta
Shiladitya Sengupta
Significance: The ability to identify responders and nonresponders very early during chemotherapy by direct visualization of the activity of the anticancer treatment and to switch, if necessary, to a regimen that is effective can have a significant effect on the outcome as well as quality of life. Current approaches to quantify response rely on imaging techniques that fail to detect very early responses. In the case of immunotherapy, the early anatomical readout is often discordant with the biological response. This study describes a self-reporting nanomedicine that not only delivers chemotherapy or immunotherapy to the tumor but also reports back on its efficacy in real time, thereby identifying responders and nonresponders early on.

16 July 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
RRRituparna Sinha Roy
Rituparna Sinha Roy
SSShivani Soni
Shivani Soni
RHRania Harfouche
Rania Harfouche
PVPooja R. Vasudevan
Pooja R. Vasudevan
OHOliver Holmes
Oliver Holmes
SSShiladitya Sengupta
Shiladitya Sengupta
Therapeutic angiogenesis is an emerging paradigm for the management of ischemic pathologies. Proangiogenic Therapy is limited, however, by the current inability to deliver angiogenic factors in a sustained manner at the site of pathology. In this study, we investigated a unique nonglycosylated active fragment of hepatocyte growth factor/scatter factor, 1K1, which acts as a potent angiogenic agent in vitro and in a zebrafish embryo and a murine matrigel implant model. Furthermore, we demonstrate that nanoformulating 1K1 for sustained release temporally alters downstream signaling through the mitogen activated protein kinase pathway, and amplifies the angiogenic outcome. Merging protein engineering and nanotechnology offers exciting possibilities for the treatment of ischemic disease, and furthermore allows the selective targeting of downstream signaling pathways, which translates into discrete phenotypes.

30 November 2015 in AI & SOCIETY
Verified
Journal Article
Closed access
PDF file
RMRaghunath Anant Mashelkar
Raghunath Anant Mashelkar